Prognostic Implications of Cutaneous Metastases in Colorectal Cancer: A Comprehensive Systematic Review and Meta-Analysis

IF 3.1 2区医学 Q2 ONCOLOGY

Cancer Medicine Pub Date : 2025-09-12 DOI:10.1002/cam4.71197

Elliot Tokarski, Pierre-Louis Conan, Hugo Picchi, Brice Malgras, Evelyne Peroux, Anne-Cecile Ezanno

{"title":"Prognostic Implications of Cutaneous Metastases in Colorectal Cancer: A Comprehensive Systematic Review and Meta-Analysis","authors":"Elliot Tokarski, Pierre-Louis Conan, Hugo Picchi, Brice Malgras, Evelyne Peroux, Anne-Cecile Ezanno","doi":"10.1002/cam4.71197","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Management of cutaneous metastases in colorectal cancer is crucial because it can significantly impact patient survival.</p>\n </section>\n \n <section>\n \n <h3> Objective</h3>\n \n <p>To assess the global prognosis of skin metastases among patients treated for colorectal cancer.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A systematic review of the PubMed database only was conducted for English articles or reports published between 1 January 1990 and 1 November 2023. Reports concerning clinical outcomes of patients with cutaneous metastases of colorectal cancer and systematic reviews of the literature were included. Study characteristics and results of eligible studies were independently extracted by two reviewers (A.C.E., E.T.). The histology, locations, and prognosis of patients with skin metastases of colorectal cancer were analyzed.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Data were obtained from almost 100 articles, most of which were case reports. Follow-up data were available for 62 patients. The most common site was rectal adenocarcinoma (58%), followed by right and left colon adenocarcinomas. A significant number of these metastases were metachronous (61%). The median time to death was 5.5 months [interquartile range, 3–10], ranging from 1 to 60 months. Treatment of cutaneous metastases, even if associated with other metastases, significantly improved overall survival (<i>p</i> < 0.001; hazard ratio, 0.15), regardless of the proposed treatment.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>We carried out the most extensive review of the literature concerning cutaneous metastases of colorectal cancer to date. The review showed that cutaneous metastases are associated with a poor prognosis and short survival time. We suggest treating patients with cutaneous metastasis as if such metastasis were a surrogate marker or sentinel for aggressive metastatic disease.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 18","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.71197","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.71197","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Management of cutaneous metastases in colorectal cancer is crucial because it can significantly impact patient survival.

Objective

To assess the global prognosis of skin metastases among patients treated for colorectal cancer.

Methods

A systematic review of the PubMed database only was conducted for English articles or reports published between 1 January 1990 and 1 November 2023. Reports concerning clinical outcomes of patients with cutaneous metastases of colorectal cancer and systematic reviews of the literature were included. Study characteristics and results of eligible studies were independently extracted by two reviewers (A.C.E., E.T.). The histology, locations, and prognosis of patients with skin metastases of colorectal cancer were analyzed.

Results

Data were obtained from almost 100 articles, most of which were case reports. Follow-up data were available for 62 patients. The most common site was rectal adenocarcinoma (58%), followed by right and left colon adenocarcinomas. A significant number of these metastases were metachronous (61%). The median time to death was 5.5 months [interquartile range, 3–10], ranging from 1 to 60 months. Treatment of cutaneous metastases, even if associated with other metastases, significantly improved overall survival (p < 0.001; hazard ratio, 0.15), regardless of the proposed treatment.

Conclusions

We carried out the most extensive review of the literature concerning cutaneous metastases of colorectal cancer to date. The review showed that cutaneous metastases are associated with a poor prognosis and short survival time. We suggest treating patients with cutaneous metastasis as if such metastasis were a surrogate marker or sentinel for aggressive metastatic disease.

Abstract Image

查看原文本刊更多论文

结直肠癌皮肤转移对预后的影响：一项全面的系统回顾和荟萃分析

结直肠癌皮肤转移的处理至关重要，因为它可以显著影响患者的生存。目的探讨结直肠癌患者皮肤转移的总体预后。方法对PubMed数据库中1990年1月1日至2023年11月1日发表的英文文章或报告进行系统评价。包括结直肠癌皮肤转移患者的临床结果报告和文献的系统综述。两名审稿人（A.C.E， E.T.）独立提取符合条件的研究特征和结果。分析结直肠癌皮肤转移患者的组织学、部位及预后。结果数据来源于近100篇文献，大部分为病例报告。有62例患者的随访数据。最常见的部位是直肠腺癌（58%），其次是右、左结肠腺癌。这些转移中有相当一部分是异时性的（61%）。中位死亡时间为5.5个月[四分位数间距，3-10]，范围为1 - 60个月。无论采用何种治疗方法，治疗皮肤转移瘤，即使伴有其他转移，也能显著提高总生存率（p < 0.001；风险比为0.15）。结论：我们对迄今为止有关结直肠癌皮肤转移的文献进行了最广泛的回顾。回顾显示，皮肤转移与预后差和生存时间短有关。我们建议治疗患者的皮肤转移，如果这样的转移是一个替代标志物或前哨侵袭性转移性疾病。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.